Inactivation of Middle East respiratory syndrome-coronavirus in human plasma using amotosalen and ultraviolet A light

Transfusion

Volumn 58, Issue 1, 2018, Pages 52-59

  Hindawi, Salwa I ^a,b   Hashem, Anwar M ^b,c   Damanhouri, Ghazi A ^b   El Kafrawy, Sherif A ^c,d   Tolah, Ahmed M ^c   Hassan, Ahmed M ^c   Azhar, Esam I ^c  

^a KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

^b King Abdulaziz University   (Saudi Arabia)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d MENOUFIA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; FUROCOUMARIN DERIVATIVE; PHOTOSENSITIZING AGENT; VIRUS RNA;

ANIMAL; BLOOD; CHLOROCEBUS AETHIOPS; CYTOPATHOGENIC EFFECT; DRUG EFFECT; EVALUATION STUDY; GROWTH, DEVELOPMENT AND AGING; HUMAN; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PLASMA; RADIATION RESPONSE; REAL TIME POLYMERASE CHAIN REACTION; ULTRAVIOLET RADIATION; VERO CELL LINE; VIRAL PLAQUE ASSAY; VIROLOGY; VIRUS INACTIVATION; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; CERCOPITHECUS AETHIOPS; CYTOPATHOGENIC EFFECT, VIRAL; FUROCOUMARINS; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PHOTOSENSITIZING AGENTS; PLASMA; REAL-TIME POLYMERASE CHAIN REACTION; RNA, VIRAL; ULTRAVIOLET RAYS; VERO CELLS; VIRAL LOAD; VIRAL PLAQUE ASSAY; VIRUS INACTIVATION; VIRUS REPLICATION;

EID: 85038024639     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14422     Document Type: Article

References (47)

1. Torane VP, Shastri JS. Comparison of ELISA and rapid screening tests for the diagnosis of HIV, hepatitis B and hepatitis C among healthy blood donors in a tertiary care hospital in Mumbai. Indian J Med Microbiol 2008;26:284-5.
2. Tessema B, Yismaw G, Kassu A, et al. Seroprevalence of HIV, HBV, HCV and syphilis infections among blood donors at Gondar University Teaching Hospital, Northwest Ethiopia: declining trends over a period of five years. BMC Infect Dis. England 2010;10:111.
3. Paty MC. [The expansion of vector-borne diseases and the implications for blood transfusion safety: the case of West Nile virus, dengue and chikungunya]. Transfus Clin Biol 2013;20:165-73.
4. Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814-20.
5. Middle East respiratory syndrome coronavirus (MERS-CoV) [Internet]. Geneva: World Health Organization; 2017 [cited 2017 Feb 24]. Available from: http://www.who.int/emergencies/mers-cov/en/.
6. Statistics [Internet]. Riyadh: Saudi Ministry of Health, Command & Control Center (CCC). 2014 [cited 2017 Feb 24]. Available from: http://www.moh.gov.sa/en/CCC/PressReleases/Pages/default.aspx.
7. Mackay IM, Arden KE. Middle East respiratory syndrome: an emerging coronavirus infection tracked by the crowd. Virus Res 2015;202:60-88.
8. Almekhlafi GA, Albarrak MM, Mandourah Y, et al. Presentation and outcome of Middle East respiratory syndrome in Saudi intensive care unit patients. Crit Care 2016;20:123.
9. Arabi YM, Balkhy HH, Hayden FG, et al. Middle East respiratory syndrome. N Engl J Med 2017;376:584-94.
10. Shehata MM, Gomaa MR, Ali MA, et al. Middle East respiratory syndrome coronavirus: a comprehensive review. Front Med 2016;10:120-36.
11. Lessler J, Salje H, Van Kerkhove MD, et al. Estimating the severity and subclinical burden of Middle East respiratory syndrome coronavirus infection in the Kingdom of Saudi Arabia. Am J Epidemiol 2016;183:657-63.
12. Azhar EI, El-Kafrawy SA, Farraj SA, et al. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med 2014;370:2499-505.
13. Müller MA, Corman VM, Jores J, et al. MERS coronavirus neutralizing antibodies in camels, Eastern Africa, 1983-1997. Emerg Infect Dis 2014;20:2093-5.
14. Hemida MG, Perera RA, Al Jassim RA, et al. Seroepidemiology of Middle East respiratory syndrome (MERS) coronavirus in Saudi Arabia (1993) and Australia (2014) and characterisation of assay specificity. Euro Surveill 2014;19. pii: 20828.
15. Alagaili AN, Briese T, Mishra N, et al. Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. MBio 2014;5:e00884-14.
16. Sabir JS, Lam TT, Ahmed MM, et al. Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia. Science 2016;351:81-4.
17. Alraddadi BM, Watson JT, Almarashi A, et al. Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. Emerg Infect Dis 2016;22:49-55.
18. Memish ZA, Assiri AM, Al-Tawfiq JA. Middle East respiratory syndrome coronavirus (MERS-CoV) viral shedding in the respiratory tract: an observational analysis with infection control implications. Int J Infect Dis 2014;29:307-8.
19. Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother 2015;70:2129-32.
20. Corman VM, Albarrak AM, Omrani AS, et al. Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection. Clin Infect Dis 2016;62:477-83.
21. Kim SY, Park SJ, Cho SY, et al. Viral RNA in blood as indicator of severe outcome in Middle East respiratory syndrome coronavirus infection. Emerg Infect Dis 2016;22:1813-6.
22. Min CK, Cheon S, Ha NY, et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep 2016;6:25359.
23. Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967-76.
24. Berger A, Drosten C, Doerr HW, et al. Severe acute respiratory syndrome (SARS)—paradigm of an emerging viral infection. J Clin Virol 2004;29:13-22.
25. Stramer SL. Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections. ISBT Sci Ser 2014;9:30-6.
26. Irsch J, Lin L. Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT Blood System™. Transfus Med Hemother 2011;38:19-31.
27. Pinna D, Sampson-Johannes A, Clementi M, et al. Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates. Transfus Med 2005;15:269-76.
28. Musso D, Richard V, Broult J, et al. Inactivation of dengue virus in plasma with amotosalen and ultraviolet A illumination. Transfusion 2014;54:2924-30.
29. Aubry M, Richard V, Green J, et al. Inactivation of Zika virus in plasma with amotosalen and ultraviolet A illumination. Transfusion 2016;56:33-40.
30. Schlenke P. Pathogen inactivation technologies for cellular blood components: an update. Transfus Med Hemother 2014;41:309-25.
31. Mintz PD, Neff A, MacKenzie M, et al. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006;46:1693-704.
32. Cazenave JP, Waller C, Kientz D, et al. An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Transfusion 2010;50:1210-9.
33. Bost V, Chavarin P, Boussoulade F, et al. Independent evaluation of tolerance of therapeutic plasma inactivated by amotosalen-HCl-UVA (Intercept ™) over a 5-year period of extensive delivery. Vox Sang 2015;109:414-6.
34. Al-amri SS, Abbas AT, Siddiq LA, et al. Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein. Sci Rep 2017;7:44875.
35. Coleman CM, Frieman MB. Growth and quantification of MERS-CoV infection. Curr Protoc Microbiol 2015;37:15E.2.1-9.
36. Zhou J, Chu H, Li C, et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J Infect Dis 2014;209:1331-42.
37. Corman VM, Eckerle I, Bleicker T, et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill 2012;17. pii: 20285.
38. Corman VM, Müller MA, Costabel U, et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill 2012;17. pii: 20334.
39. Centers for Disease Control and Prevention (CDC). HIV transmission through transfusion—Missouri and Colorado, 2008. MMWR Morb Mortal Wkly 2010;59:1335-9.
40. Bloch EM, Vermeulen M, Murphy E. Blood transfusion safety in Africa: a literature review of infectious disease and organizational challenges. Transfus Med Rev 2012;26:164-80.
41. Woolhouse ME, Haydon DT, Antia R. Emerging pathogens: the epidemiology and evolution of species jumps. Trends Ecol Evol 2005;20:238-44.
42. Motta IJ, Spencer BR, Cordeiro da Silva SG, et al. Evidence for transmission of Zika virus by platelet transfusion. N Engl J Med 2016;375:1101-3.
43. European Directorate for the Quality of Medicines and Healthcare. Guide to the preparation, use, and quality assurance of blood components. 17th ed. Strasbourg: Council of Europe; 2013.
44. Chu H, Zhou J, Wong BH, et al. Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response. Virology 2014;454-455:197-205.
45. Chu H, Zhou J, Wong BH, et al. Middle East respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways. J Infect Dis 2016;213:904-14.
46. Moustafa A, Xie C, Kirkness E, et al. The blood DNA virome in 8,000 humans. PLoS Pathog 2017;13:e1006292.
47. Keil SD, Bowen R, Marschner S. Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment. Transfusion 2016;56:2948-52.